Citations for MIA Paper on Long-term Effects of Antipsychotics

This is list of citations for the “MIA Paper, The Case Against Antipsychotics: A Review of their Long-term Effects.” It provides links to either the pubmed abstract for the article, or to a pdf of the study that can be downloaded.

1. Leucht, S. “Antipsychotic drugs versus placebo for relapse prevention in schizophrenia.” Lancet 379 (2012):2063-71.

2. Stip, E. “Happy birthday neuroleptics! 50 years later: la folie du doute.Eur Psychiatry 17 (2002):115-9.

3. Cole, J, editor. Psychopharmacology. Washington, DC: National Academy of Sciences (1959), 142.

4. Cole, ibid, 386-387.

5. Lehrman, N. “Follow-up of brief and prolonged psychiatric hospitalization,” Comp Psychiatry 2 (1961):227-40.

6. Cole, J. The National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 10 (1964): 246–61.

7. Schooler, N. “One Year After Discharge.Am J Psychiatry 123 (1967):986-95.

8. Gardos, G. “Maintenance Antipsychotic Therapy: is the cure worse than the disease?”  Am J Psychiatry 133 (1977):32-6.

9. Gardos, G., Cole J. “Withdrawal syndromes associated with antipsychotic drugs.” Am J Psychiatry 135 (1978):1321-24. Also see Gardos, ibid.

10. Bockoven, J. “Comparison of Two Five-Year Follow-up Studies.” Am J Psychiatry 132 (1975):796-801.

11. Rappaport, M. “Are There Schizophrenics for Whom Drugs May be Unnecessary or Contraindicated?” Int Pharmacopsychiatry 13 (1978):100-11.

12. Mathews, S. “A Non-Neuroleptic Treatment for Schizophrenia.” Schizophr Bull 5 (1979):322-32.

13. Bola, J. “Treatment of Acute Psychosis Without Neuroleptics.” J Nerv Ment Dis 191 (2003):219-29.

14. Carpenter, W. “The Treatment of Acute Schizophrenia Without Drugs.” Am J Psychiatry 134 (1977): 14-20.

15. Creese, I. “Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.” Science 192 (1976):481-483.

16. Seeman, P. “Antipsychotic drug doses and neuroleptic/dopamine receptors.” Nature 261 (1976):177-179.

17. Bowers, M. “Central dopamine turnover in schizophrenic syndromes.” Arch Gen Psychiatry 31 (1974):50-54.

18. Post, R. “Cerebrospinal fluid amine metabolites in acute schizophrenia.” Arch Gen Psychiatry 32 (1975):1063-1068.

19. Haracz, J. “The dopamine hypothesis: an overview of studies with schizophrenic patients.” Schizophr Bull 8 (1982): 438-458.

20. Lee, T. “Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains,Nature 374 (1978):897-900.

21. Burt, D. “Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.” Science 196 (1977):326-327.

22. Porceddu, M. “[3H]SCH 23390 binding sites increase after chronic blockade of d-1 dopamine receptors.” Eur J Pharmacol 118 (1985):367-370.

23. MacKay, A. “Increased brain dopamine and dopamine receptors in schizophrenia.” Arch Gen Psychiatry 39 (1982):991-997.

24. Kornhuber, J. “3H-spiperone binding sites in post-mortem brains from schizophrenic patients.” J Neural Transm 75 (1989):1-10.

25. Martinot, J. “Striatal D2 dopaminergic receptors assessed with positron emission tomography and bromospiperone in untreated schizophrenic patients.” Am J Psychiatry 147 (1990):44-50.

26. Farde L. “D2 dopamine receptors in neuroleptic-naïve schizophrenic patients.” Arch Gen Psychiatry 47 (1990):213-219.

27. Hietala, J. “Striatal D2 dopamine receptor characteristics in neuroleptic-naïve schizophrenic patients studied with positron emission tomography.” Arch Gen Psychiatry 51 (1994):116-123.

28. Chouinard, G. “Neuroleptic-Induced Supersensitivity Psychosis.” Am J Psychiatry 135 (1978):1409-10.

29. Chouinard, G. “Neuroleptic-Induced Supersensitivity Psychosis.Am J Psychiatry 137 (1980):16-20.

30. Chouinard, G. “Neuroleptic-induced supersensitivity psychosis, the “hump course” and tardive dyskinesia.” J Clin Psychopharmacol 2 (1982):143-44.

31. Chouinard, G. “Severe cases of neuroleptic-induced supersensitivity psychosis.” Schizophr Res 5 (1991):21-33.

32. Leff, J. “The International Pilot Study of Schizophrenia.” Psychol Med 22 (1992):131–45.

33. Jablensky, A. “Schizophrenia: Manifestations, Incidence and Course in Different Cultures.” Psychol Med 20, monograph (1992):1-95.

34.  Jablensky, ibid. See tables on page 60 for medication usage by individual centers; see table on page 64 for medication usage by developing and developed countries.

35. Hopper, K. “Revisiting the developed versus developing country distinction in course and outcome in schizophrenia.” Schizophr Bull 26 (2000):835-46.

36. Chakos, M. “Increase in Caudate Nuclei Volumes of First-Episode Schizophrenia Patients Taking Antipsychotic Drugs.” Am J Psychiatry 151 (1994):1430-6..

37. Madsen, A. “Neuroleptics in Progressive Structural Brain Abnormalities in Psychiatric Illness.” The Lancet 352 (1998):784-5

38. Gur, R. “A Followup Magnetic Resonance Imaging Study of Schizophrenia.” Arch Gen Psychiatry 55 (1998):145-52.

39. Gur, R. “Subcortical Volumes in Neuroleptic Naive and Treated Patients with Scizophrenia.”  Am J Psychiatry 155 (1998):1711-7.

40. Ho, B. “Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome.” Arch Gen Psychiatry 60 (2003):585-594.

41. Ho, B. “Long-term Antipsychotic Treatment and Brain Volumes.” Arch Gen Psych 68 (2011): 128-37.

42. V. Aderhold. “Heinzfrontale Hirnvolumenminderung durch Antipsycotika?” Der Nervenarzt. May, 2014

43. Seeman, P. “Dopamine Supersensitivity Correlates with D2 HIGH States, Implying Many Paths to Psychosis.” Proceedings of the National Academy of Science 102 (2005):3513-18.

44. Samaha, A. “Breakthrough Dopamine Supersensitivity During Ongoing Antipsychotic Treatment Leads to Treatment Failure Over Time.” The Journal of Neuroscience 27 (2007): 2979-86.

45.  Harrow, M. “Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications.” J Nerv Ment Dis 195 (2007):406-414.

46.  M. Harrow. “Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study.” Psychol Med 42 (2012): 2145-55.

47. Harrow, ibid, 2012.

48. Harrow, ibid, 2007.

49. Harrow, M. “Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis?Psychol Med 44 (2014): 3007-16.

50. Harrow, ibid, 2012.

51. Harrow, M. ”Pharmacological Treatment for Psychosis: Emerging Perspectives.” Presentation in Syracuse, NY, October 2, 2014.

52. Harrow, ibid, 2007.

53.  Harrow, ibid, 2007.

54.  Harrow, ibid, 2007.

55. Harrow, ibid, 2007.

56.  Harrow, M. “Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?Schizophr Bull 39 (2013):962-5.

57. Wunderink, L. “Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation of maintenance treatment strategy.” 
JAMA Psychiatry, 70 (2013): 913–20.

58. Gleeson, J. “A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients.” Schizophrenia Bulletin 39 (2013):436-48.

59.  Seikkula, J. “Five-year experience of first-episode non-affective psychosis in open-dialogue approach.” Psychotherapy Research 16 (2006):214-28.

60.  Ran, M. “Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China.” Br J Psychiatry 207 (2015): 495-500.

61.  Sohler, N. “Weighing the evidence for harm from long-term treatment with antipsychotic medications: a systematic review.” Amer J of Orthopsychiatry, first online publication Dec. 14, 2015.

62. Pritchard, M. “Prognosis of schizophrenia before and after pharmacotherapy: II. Three-year follow-up.” Br J Psychiatry 113 (1967):1353-59.

63. Odegard, O. “Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of the psychotropic drugs.Am J Psychiatry 120 (1964):772-78.

64. McWalter, H. “Outcomes of treatment of schizophrenia in a north-east Scottish mental hospital.” Am J Psychiatry 118 (1961):529-533.

65. Engelhardt, D. “Phenothiazines in prevention of psychiatric hospitalization IV. Delay or prevention of hospitalization—a reevaluation.” Arch Gen Psychiatry 16 (1967):98-101.

66. Hogarty, G. “Drug and sociotherapy in the aftercare of schizophrenic patients II. Two-year relapse rates.” Arch Gen Psychiatry 31 (1974):603-8.

67. Crow, T. “A randomized control trial of prophylactic neuroleptic treatment.Br J Psychiatry 148 (1986):120-7.

68. Nishikawa T. “Prophylactic effect of neuroleptics in symptom-free schizophrenics.” Psychopharmacology 77 (1982):301-4.

69. Boonstra, G. “Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomized trial.” Int J Psychiatry Clin Pract 15 (2011):128-34.

70. Carpenter, W. “A comparative trial of pharmacologic strategies in schizophrenia.” Arch Gen Psychiatry 144 (1987):1466-70.

71. Pietzcker, A. “Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia—2-year results of a German multicenter study.” J Psychiatric Research 27 (1993):321-39.

72. May, P. “Schizophrenia. A follow-up study of the results of five forms of treatment.” Arch Gen Psychiatry 38 (1981):776-84.

73. Moilanen, J. “Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication—a 10-year follow-up of the Northern Finland 1966 birth cohort study.” European Psychiatry 28 (2013):53-58.

74. Molainen, J. “The use of antipsychotic medication and its association with outcomes and brain morphometry in schizophrenia—the northern Finland birth cohort 1966 study.” PhD dissertation, University of Oulu, Finland, 2016.

75. Tiihonen, J. “Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333 (2006):224-30.